High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma.
High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma.
复制标题
血清中白介素 10 水平高预示多发性骨髓瘤预后不良。
DOI：
10.1038/bjc.2016.11
复制
发表时间：
2016-02-16
影响因子：
8.8
通讯作者：
Lu Y
中科院分区：
文献类型：
--
作者：
Wang H;Wang L;Chi PD;Wang WD;Chen XQ;Geng QR;Xia ZJ;Lu Y
白细胞介素-10（IL-10）是一种抑制性炎症细胞因子，在多发性骨髓瘤（MM）的免疫抑制微环境中起重要作用。血清IL-10水平是否能预测MM患者的治疗反应和生存结局尚需进一步研究。采用酶联免疫吸附试验检测188例初诊MM患者血清IL-10水平。IL-10预测生存的最佳临界值为169.69 pg ml-1，曲线下面积（AUC）值为0.747（P<0.001）。总共有92名患者（48.9%）被归类为高IL-10组（>169.96 pg ml−1），96名患者（51.1%）被归类为低IL-10组（> 169.96 pg ml−1）。低IL-10组总有效率（ORR）为79.2%，显著高于高IL-10组（53.3%，P<0.001）。低IL-10组患者的3年无进展生存率（PFS）为69.3%，高于高IL-10组的13.3%（P<0.001）; 3年总生存率（OS）为93.6%，高于高IL-10组的51.9%（P<0.001）。多变量分析显示，诊断时血清IL-10水平>169.96 pg ml−1和某些细胞遗传学异常是PFS和OS的两个不利因素。我们的数据表明，诊断时血清IL-10是MM预后的一个新的、强有力的预测因素。
Interleukin-10 (IL-10) is a inhibiting inflammatory cytokine that plays an important role in immune suppressive microenvironment in multiple myeloma (MM). Whether the level of serum IL-10 could predict treatment response and survival outcomes or not needs to be investigated in MM patients. The level of IL-10 in serum was measured using enzyme-linked immunosorbent assay in 188 patients with newly diagnosed MM. The best cutoff value for IL-10 in predicting survival is 169.69 pg ml−1 with an area under the curve (AUC) value of 0.747 (P<0.001). In all, 92 patients (48.9%) were classified as high-IL-10 group (>169.96 pg ml−1) and 96 patients (51.1%) as low-IL-10 group (⩽169.96 pg ml−1). The overall response rate (ORR) was 79.2% in low-IL-10 group, significantly higher than that in high-IL-10 group (53.3%, P<0.001). Patients in low-IL-10 group had significantly better survival compared with those in high-IL-10 group (3-year PFS rate: 69.3% vs 13.3%, P<0.001; 3-year OS rate: 93.6% vs 51.9%, P<0.001). Multivariate analysis revealed that serum IL-10 level >169.96 pg ml−1 at diagnosis and certain cytogenetic abnormalities were two adverse factors for PFS and OS. Our data suggest that serum IL-10 at diagnosis is a novel, powerful predictor of prognosis for MM.